New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RHHBY;ILMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 29, 2015
05:47 EDTRHHBYRoche, Qualcomm collaborate on remote patient monitoring
Subscribe for More Information
January 28, 2015
09:22 EDTILMNIllumina price target raised to $230 from $200 at Wedbush
Subscribe for More Information
08:40 EDTILMNIllumina price target raised to $221 from $192 at Janney Capital
Subscribe for More Information
08:27 EDTILMNIllumina price target raised to $234 from $220 at BofA/Merrill
BofA/Merrill raised Buy rated Illumina's price target to $234 citing strong Q4 organic sales momentum.
08:07 EDTRHHBYRoche unit receives orphan status for alectinib
Subscribe for More Information
07:59 EDTILMNIllumina price target raised to $225 from $195 at Leerink
Subscribe for More Information
05:49 EDTRHHBYRoche sees 2015 sales growth in low- to mid-single digit
Roche expects sales to grow low- to mid-single digit, at constant exchange rates for 2015. Core earnings per share are targeted to grow ahead of sales at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:48 EDTRHHBYRoche reports 2014 core EPS CHF14.29 vs. CHF14.27 last year
Subscribe for More Information
January 27, 2015
16:09 EDTILMNIllumina sees FY15 non-GAAP EPS $3.12-$3.18, consensus $3.20
For FY15 the Company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP EPS of $3.12-$3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%.
16:08 EDTILMNIllumina reports Q4 non-GAAP EPS 87c, consensus 78c
Reports Q4 revenue $512M, consensus $507.65M.
14:00 EDTRHHBYRoche to hold a meeting with a conference call hookup
Subscribe for More Information
January 26, 2015
05:15 EDTRHHBYRoche receives FDA clearance for next generation cobas MRSA/SA test
Subscribe for More Information
January 23, 2015
15:46 EDTILMNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
08:17 EDTRHHBYRoche management to meet with JPMorgan
Meeting to be held in New York on January 29 hosted by JPMorgan.
January 21, 2015
10:24 EDTILMNIllumina pulls back following State of the Union address
Shares of Illumina (ILMN) rose yesterday after a biotech industry website reported that President Obama might unveil a major new genomics project during his State of the Union address last night. That speculation was backed as a possibility by an analyst at Wells Fargo ahead of last night's address. In the speech, President Obama unveiled what he called his Precision Medicine Initiative, which relies on genomics to "deliver(s) the right treatment at the right time." Obama spent far more time, however, discussing economic growth and foreign relations than healthcare. Illumina shares are down 3% to $190.64 in early trading today.
09:02 EDTRHHBYRoche's Ventana seeks FDA premarket approval for ALK IHC lung cancer assay
Roche Group member Ventana Medical Systems announced its FDA submission for premarket approval of the Ventana ALK CDx Assay. The companion diagnostic immunohistochemistry test is designed to identify ALK1-positive lung cancer patients that may benefit from treatment with targeted therapy that inhibits the ALK gene. This submission was the fourth and final module and application required by the FDA's PMA process.
January 20, 2015
13:45 EDTILMNIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.
January 16, 2015
16:36 EDTRHHBYMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
06:21 EDTRHHBYRoche acquires Trophos for EUR120M plus contingent payments
Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime, TRO19622, which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology. Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120M, plus additional contingent payments of up to EUR 350M based on achievement of certain predetermined milestones.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use